An Ayurvedic poly-herbal formulation, NEERI-KFT, has the potential to not only slow down the progression of chronic kidney disease but also restore normalcy in functional parameters of the vital organ, a team of researchers has claimed.
In a review published in the latest edition of Saudi Journal of Biological Sciences, they said "phytopharmacological evaluation of NEERI-KFT suggests that it exhibits substantial potential against oxidative and inflammatory stress induced apoptosis by exerting antioxidant, nephroprotective and immunomodulatory effects...in the patients associated with renal dysfunction or chronic kidney disease (CKD)".
The NEERI-KFT, a herbal medicine extracted from plants, has been found to correct oxidative as well as inflammatory stress known for reducing body's immunity, said the authors after drawing data on the formulation for kidney ailments from more than five electronic databases such as Science Direct, Google Scholar, Elsevier, PubMed, Springer, ACS publication from published database between 2000 and 2020.
Buy Online► Aimil Neeri KFT Syrup
The study, 'A systematic review on nephroprotective AYUSH drugs as constituents of NEERI-KFT' not only examined the impact of the herbal extract of NEERI-KFT prepared by the AIMIL Pharma interventions on patients, but also dwelled in detail the adverse events of the modern medicine used for the management of the kidney ailments.
The study also highlighted the herbal drug's efficacy in reducing "serum creatinine, blood urea, and serum uric acid as compared to placebo group" and described "its well-tolerated effect with no adverse hematological or biochemical abnormalities occurred to any subjects during clinical trial".
"It can be suggested that NEERI-KFT can be an alternative and complementary therapy at end-stage renal disease (ESRD) or complete loss of kidney function where frequent dialysis of renal transplant remains only a single option for continued survival CKD patients," researchers said.
K.K. Sharma, AIMIL Pharma Managing Director, attributed this to the "more than 20 different potent herbs like haridra, varuna, shirish, gokhru, punarnava and anantamul to name a few in the formulation which are known for their nephro corrective, anti-inflammatory and antioxidant properties and reparative regeneration of kidney cells.
Also, Read This► किडनी के लिए संजीवनी बनी आयुर्वेदिक दवा नीरी केएफटी : अध्ययन
It was after a string of stringent tests that this formulation has been developed to provide relief to kidney patients, he said.
K.N. Dwivedi from Banaras Hindu University said the herbal ingredients in NEERI-KFT are loaded with many anti-oxidants besides medicinal values which not only strengthen kidney but liver also.
"This is a very unique drug and we have found it very effective in our study also," he added.
Read More► Aimil Neeri KFT Syrup: Benefits, Side Effects, Composition and Dosage
Hong Kong, Aug 17 (IANS) The risk of rare Bell's palsy after taking Pfizer's Covid vaccination is very less, finds a study published in The Lancet Infectious Diseases journal, suggesting that the protective effects of the vaccines far outweigh the risk.Bell's palsy is the sudden onset of one-sided facial paralysis. In the majority of cases (70 per cent), the condition resolves itself within six months without treatment and the chance of recovery is even higher (90 per cent) if patients receive early treatment with corticosteroids.Researchers at the University of Hong Kong analysed cases of Bell's palsy related to the two approved vaccines in Hong Kong -- China's CoronaVac and US-based Pfizer.The team found that for every 100,000 people vaccinated with China's inactivated vaccine CoronaVac, an additional 4.8 people may develop the condition, but for the Pfizer-BioNTech vaccine, the increased risk was equivalent to an additional 2 cases per 100,000 people vaccinated.For the study, the team included 298 Bell's palsy cases and 1,181 matched controls from 2010-2020.The team estimated the background risk of Bell's palsy in Hong Kong -- around 27 cases per 100,000 people, per year. Global estimates range from 15-30 cases per 100,000 people, per year.The study found that receiving CoronaVac was associated with 2.4 times increased risk of Bell's palsy (95 per cent) whereas receiving Pfizer vaccine was not associated with a significantly increased risk."Our study suggests a small increased risk of Bell's palsy associated with CoronaVac vaccination. Nevertheless, Bell's palsy remains a rare, mostly temporary, adverse event. All evidence to date, from multiple studies, shows that the beneficial and protective effects of the inactivated Covid-19 vaccine far outweigh any risks," said lead author Professor Ian Chi Kei Wong, from the varsity."Ongoing surveillance, through pharmacovigilance studies such as ours are important to calculate with increasing levels of confidence the risks of rare adverse events," Wong added.However, the team noted that the study is limited to patients with a new diagnosis of Bell's palsy in Hong Kong, so further studies in other regions should be done to confirm the findings.The US Federal Drug Administration (FDA) does not consider a clear causal association between the condition and vaccines by Pfizer-BioNTech and the Moderna, but recommends ongoing surveillance. Acute partial facial paralysis is reported as a rare side effect of both vaccines by the European Medicines Agency.--IANSrvt/vd
London, Aug 15 (IANS) Researchers at University College London conducted a study of people with cerebral venous thrombosis (CVT) following Covid-19 vaccination, to provide a clearer guide for clinicians trying to diagnose and treat such patients.The research, published in The Lancet, is the most detailed account of the characteristics of CVT, when it is caused by the novel condition vaccine-induced immune thrombotic thrombocytopenia (VITT).VITT is a condition characterised by a blockage of the veins and a marked reduction of platelets, blood components which are an important part of the blood clotting system. The commonest and severest manifestation of VITT is CVT, in which veins draining blood from the brain become blocked.The study looks in detail at 70 patients with VITT-associated CVT following vaccination, who were then compared to 25 patients with CVT but without the evidence of VITT.The study provides support for the three principles of treatment established so far by the Expert Hematology Panel, based on early work at UCL and two other European sites.The use of non-heparin-based anticoagulation; give treatments to try to reduce the level of the abnormal antibody that is implicated in this condition; and avoid the strategy of trying to bring the platelet count back up to normal levels by giving platelet transfusions."We found that those patients who were given intravenous immunoglobulin -- the treatment in which the body is flooded with normal antibodies to try to reduce the effects of the abnormal one -- were more likely to leave hospital alive and able to live an independent life rather than depending on carers or family to look after them," Dr Alastair Webb, consultant neurologist at the John Radcliffe Hospital in Oxford said.On the other hand, platelet transfusions were associated with a worse outcome in patients with VITT-associated CVT. Although observational data cannot prove harm from this treatment approach, the study provides support for the concern that has already been raised about the potential harm of platelet transfusions.However, the researchers also suggest that some treatments such as intravenous immunoglobulin seem to be associated with better outcomes but caution against reading too much into the findings of the observational study, saying that reliable evidence about treatments can only be obtained in a randomised clinical trial.--IANSrvt/skp/
New Delhi, Aug 15 (IANS) Union Minister for Social Justice and Empowerment Dr. Virendra Kumar has launched an online portal TAPAS (Training for Augmenting Productivity and Services), developed by the National Institute of Social Defence under Ministry of Social Justice and Empowerment.Ministers of State Ramdas Athawale and Sushri Pratima Bhoumik also joined the event on Saturday.TAPAS is the initiative of National Institute of Social Defence (NISD), Ministry of Social Justice and Empowerment, to provide access to lectures by subject experts, study material and more, but in a manner that it supplements the physical classroom without compromising on the quality of teaching. The main objective of introducing the course modules is to impart training and enhance the knowledge and skills for the capacity building of the participants. It can be taken up by anyone who wishes to enhance his or her knowledge on the topics and there is no fee for joining. The five basic courses are on Drug (Substance) Abuse Prevention, Geriatric/Elderly Care, Care and Management of Dementia, Transgender Issues and on comprehensive course on Social Defence Issues.Dr. Kumar said that the online medium of learning will enable the Ministry in reaching out to an even larger number of people working in this area of social defence. He urged everyone to enroll for the course for a better understanding of issues such as substance abuse prevention, elderly care, transgender welfare and beggary prevention. "Everyone working in the field of social defence is encouraged to enroll for the course. It is an online course and one can utilise this facility to its full potential," Dr. Kumar said."In our education system, where the offline mode of teaching is so deeply entrenched, this course will lead the path of change and open up new possibilities. There is no dearth of respect and regard for our age-old guru-shishya parampara, but there's no reason why it can't be transited to the online medium. Hence, let us embark on this new journey and increase our horizon when it comes to learning and gaining knowledge," he further added.The idea of TAPAS was conceptualised at a time when exploring the online medium for work and education had become imperative due to the outbreak of Covid-19 pandemic.--IANSavr/pgh
Hyderabad, Aug 13 (IANS) Indian Immunologicals Ltd (IIL), a subsidiary of the National Dairy Development Board and a leading vaccine manufacturer, on Friday handed over the first batch of Covaxin drug substance to Bharat Biotech.The IIL said it has produced the drug substance in record time. IIL Managing Director, Dr K. Anand Kumar, handed over the first lot of Covaxin drug substance to BBIL Chairman and Managing Director, Dr Krishna Ella."It is a proud moment for IIL to have played a vital role in supporting our nation's interest during this unprecedented time. This would have not been possible without the constant support provided by Niti-Aayog, BIRAC, DBT, Mission Covid Suraksha Team, Central and State drug control authorities," Anand Kumar said."The government has worked relentlessly to provide all possible support for ramping up Covaxin production in the country and speed up the Covaxin inoculation drive. The loan license agreement by the CDSCO for Indian Immunologicals Ltd to produce Covaxin drug substance is a major milestone, achieved in a very short span of time. The DBT-BIRAC support under Mission Covid Suraksha aims to meet the Covid-19 vaccine requirement of our country. I congratulate the team for the efforts put in for this achievement," Secretary, Biotechnology, and BIRAC Chairperson, Dr Renu Swarup, said.In order to augment the Covid-19 vaccine production capacity in the country, the Central government in April requested that the IIL and Bharat Biotech International Ltd (BBIL) join hands.The IIL, in a short period of time, has performed several activities including signing of 4 agreements with BBIL, repurposing its manufacturing facility in Hyderabad, procurement of key raw materials and consumables, procurement of key equipment for the process, technology transfer, trials at R&D scale, training etc. These activities were all done at breakneck speed and production at commenced in 2021.The batches so produced at IIL's manufacturing facility have been tested both at the BBIL and the IIL and meets the quality specifications for the drug substance. The yields are more than expected, the IIL said in a statement.Dr Anand Kumar also said that IIL is also working on another Covid-19 vaccine and the animal trials are underway currently. It is expected to come out by next year for human vaccination.Under Atmanirbhar Bharat 3.0 Mission Covid Suraksha was announced by the Centre to accelerate the development and production of indigenous Covid vaccines. This is being implemented by the Department of Biotechnology.The IIL, Hyderabad, has been sanctioned a grant of Rs 60 crore towards enhancing production capabilities--IANSms/vd
New Delhi, Aug 13 (IANS) A group of 23 MPs from the Rajya Sabha met Union Health and Family Welfare Minister Mansukh Mandaviya seeking the ministry's immediate intervention to provide treatment to eligible patients diagnosed with Group 3 (a) rare genetic conditions, like Lysosomal Storage Disorders (LSDs).The Parliamentary group also submitted a memorandum to Mandaviya, drawing his attention to the urgent need for prioritisation of treatment for patients diagnosed with Group 3(a) rare genetic conditions. "Despite the notification of the much-awaited National Policy for Rare Diseases, 2021 in March this year, these patients continue to be at grave risk due to the lack of any sustainable funding mechanism for treatment," the MPs said."We would like to draw your immediate attention towards the need to prioritise treatment for at least the ultra-rare diseases -- treatable conditions which have an even lesser prevalence as compared to others; and for which the Drugs Controller General of India (DCGI) approved therapies are available in India," the memorandum stated, requesting the Union Minister to: (a) Extend the Umbrella Scheme of Rashtriya Arogya Nidhi (RAN) to all Group 3 (a) patients with treatable conditions, and (b) Transfer the unspent funds from the previous years' budgetary allocation to provide treatment for eligible patients diagnosed with treatable conditions."Several countries, including the developing economies like Brazil, Argentina, Algeria, and Egypt, have robust reimbursement mechanisms in place (often 100 per cent) for dealing with rare diseases, or have earmarked funds out of their healthcare budgets, specifically for these purposes," the members wrote, explaining that unlike diabetes or any other common ailment, the number of rare disease patients is very small. "Without any support from the government, parents of these children are left with no option but to look on in despair, despite the availability of approved therapies in India," the statement said.Led by Fauzia Khan and her party colleague from the Nationalist Congress Party (NCP). Vandana Chavan, the memorandum was signed by MPs from several states, including Maharashtra, Kerala, West Bengal, Tamil Nadu, Odisha, Rajasthan and Gujarat, to name a few."While we welcome the Government of India's efforts to mobilise funds through crowdfunding and involving corporate India and the PSUs, this process may take some time. Through this joint representation, we would like to draw your immediate attention to the condition of close to 200-odd eligible patients -- diagnosed with Group 3(a) disorders -- whose lives are at risk owing to the long delay in providing support for treatment," they stated.--IANSmiz/dpb